Table 2. Clinical manifestations of patients with MIS-C from the included case series (case number ≥10).
| Clinical manifestations | Frequency (range) | ES (95% CI) | References |
|---|---|---|---|
| Symptoms | |||
| Fever | 100% | NA | (4,14,16,22-26,28) |
| Gastrointestinal symptoms (abdominal pain, vomiting, diarrhea) | 60% to 100% | 84% (77%, 90%) | (4,14,16,22,24-26,28) |
| Rash | 50% to 81% | 65% (57%, 74%) | (4,14,16,23-26,28) |
| Conjunctivitis | 30% to 94% | 64% (47%, 82%) | (4,14,16,23-26,28) |
| Changes of the lips or oral cavity | 25% to 87% | 59% (43%, 76%) | (4,14,16,24-26,28) |
| Hand and feet anomalies | 16% to 68% | 44% (16%, 72%) | (4,23,24,28) |
| Lymphadenopathy | 10% to 60% | 37% (21%, 54%) | (4,16,23-26,28) |
| Neurological symptoms (headache, confusion, meningeal signs) | 26% to 56% | 34% (26%, 42%) | (4,14,16,23-25) |
| Asthenia | 27% to 100% | 31% (15%, 47%) | (16,22,25) |
| Respiratory symptoms (cough, rhinorrhea, dyspnoea) | 12% to 34% | 25% (14%, 36%) | (16,23-25) |
| Clinical phenotypes | |||
| Shock | 43% to 100% | 60% (47%, 73%) | (14,16,23-26,28) |
| KDSS | 44% to 57% | 51% (37%, 65%) | (4,24,28) |
| KD | 22% to 63% | 45% (27%, 63%) | (4,16,23,24,28) |
| Acute kidney failure | 16% to 70% | 42% (22%, 62%) | (14,23,24,26,28) |
| IKD | 22% to 53% | 37% (25%, 49%) | (4,16,22-24,28) |
| MAS | 56% [5/9] | NA | (4) |
| Evidence of SARS-CoV-2 infection | |||
| Serology | 53% to 100% | 86% (78%, 95%) | (4,14,16,22-26,28) |
| RT-PCR and/or serology | 78% to 100% | 85% (77%, 93%) | (14,16,23,25,28) |
| RT-PCR | 13% to 69% | 36% (26%, 46%) | (4,14,16,22-26,28) |
ES, effect size; CI, confidence interval; KDSS, Kawasaki disease shock syndrome; KD, Kawasaki disease; IKD, incomplete Kawasaki disease; MAS, macrophage activation syndrome; RT-PCR, reverse-transcriptase polymerase chain reaction; NA, not applied.